Pacira BioSciences Insider Sales Show Portfolio Rebalancing, Not Red Flag
Pacira BioSciences insider sales reveal routine portfolio rebalancing, not a downturn, while PB‑01’s breakthrough, non‑opioid pain‑management potential fuels investor optimism.
4 minutes to read